-
Recent Posts
Top Rated
Most Popular:
- Review: Bioisosteres in Drug Design
- Structure-based design of BACE inhibitors
- Discovery of PF-04691502 (PI3K/mTOR dual inhibitor)
- Characterisation of p38 switch pocket inhibitors
- Discovery of PF-04457845 (FAAH Inhibitor)
- Improved PK profile through fluorine and deuterium incorporation
- Discovery of LX2931 (Sphingosine 1-Phosphate Lyase Inhibitor) & Phase IIa Data
- Review: Gamma-secretase modulators
- Optimization of plasma protein binding (again...)
- MDM2-p53 protein-protein interaction inhibitors
Blogroll
Conferences
Intellectual Property
Journals
MedChem Resources
News
Organic Chemistry Resources
- Abbott adverse events allosteric allosteric inhibitor amine basicity Analgesic animal PK anti-viral AstraZeneca Aurora beta-secretase bioactivation BIRB-796 Boehringer Ingelheim cancer cardiotoxicity cellular potency CGRP chloro CNS penetration computational method crystal packing CYP450 Deuterium Doramapimod FAAH Fatty acid amide hydrolase fluorine free drug functional antagonist Gly-T1 gpcr hepatotoxicity hERG immunosuppressant isostere kinase kinetic isotope effect Lexicon Pharmaceuticals LipE Merck metabolism mTOR nitrile Novartis osteoarthritis P-gp p38 Pain PF-04457845 PF-3845 Pfizer Phase I Phase II Phase III POC PPB protein binding PSA reactive metabolite review RG1678 rheumatoid arthritis Roche S1P1 S1PL Schizophrenia solubility Structural alert Structure Based Design switch pocket synthesis toxicity Transporters X-ray data
Categories
Category Archives: Kinases
Discovery of PF-04691502 (PI3K/mTOR dual inhibitor)
Rapamycin and it’s analogues (or rapalogues e.g. CCI-779) modulate the phosphatidylinositol 3-kinase (PI3K) signalling cascade by binding to an allosteric site on the mTORC1 complex (Mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, forms two functional complexes, … Continue reading →
Posted in Clinical Candidates, Enzyme Inhibitors, Kinase Inhibitors, Kinases, Med Chem Strategy
|
Tagged allosteric, cancer, CCI-779, dual inhibitor, H-bond, isostere, kinase, ligand efficiency, LipE, lipophilic efficiency, metabolism, mTOR, mTORC, PDB3ML8, PDB3ML9, PF-04691502, Pfizer, phosphatidylinositol 3-kinase, pI3K, rapalogues, rapamycin, solubility, Structure Based Design, X-ray data
|
Leave a comment
TAK-733 & CH4987655 (Allosteric MEK Inhibitors)
The mitogen-activated protein kinase (MAPK) signalling cascade is one of the key pathways regulating cell proliferation and differentiation and aberrant activation of this pathway is implicated in a number of cancers. Targeting components of the cascade thus has the potential … Continue reading →
Posted in Clinical Candidates, Enzyme Inhibitors, Kinase Inhibitors, Kinases
|
Tagged allosteric, ARRY 142886, AZD-6244, cancer, CH4987655, Chugai, CNS penetration, hydroxamate, kinase, MAPK, MEK, metabolism, mTOR, PD0325901, Phase I, Phase II, RO4987655, Roche, Structure Based Design, TAK-733, Takeda, X-ray data
|
Leave a comment
Improved PK profile through fluorine and deuterium incorporation
Compound (1) was identified by scientists at Merck as a potent Aurora kinase inhibitor with the potential to be useful in the treatment of various cancers. In this paper the authors reveal that the basic amine which is key to good … Continue reading →
Posted in Kinase Inhibitors, Kinases
|
Tagged amine basicity, animal PK, Aurora, cancer, cellular potency, Deuterium, fluorine, kinase, kinetic isotope effect, Merck, metabolism, X-ray data
|
Leave a comment
